Clinical trials: Human Immunodeficiency Virus I Infection
HIV Infection
Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).
The objectives of this Phase I/II trial is to evaluate the safety, tolerability and immunogenicity of THV01 compared to placebo in HIV-1 infected patients on HAART (highly active antiretroviral therapies).
- Trial name
- NCT02054286
- Testing
- THV01-1, THV01-2
- Where
- 11 sites in Belgium, France
- Volunteers
- 38 people
- Sponsor
- Theravectys S.A.
HIV-infection/AIDS
Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy subjects.
- Trial name
- NCT01827540
- Testing
- Cenicriviroc, Dolutegravir, Midazolam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.